Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tharimmune ( (THAR) ) has issued an update.
On June 10, 2025, Tharimmune, Inc. held its Annual Meeting of Stockholders, where a quorum of 1,129,458 shares of common stock was represented. During the meeting, all seven nominees for director were elected to serve until the 2026 Annual Meeting, and the appointment of Rosenberg Rich Baker Berman P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Additionally, the Amended and Restated 2023 Omnibus Equity Incentive Plan was approved by the stockholders.
The most recent analyst rating on (THAR) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Tharimmune stock, see the THAR Stock Forecast page.
More about Tharimmune
Average Trading Volume: 124,650
Technical Sentiment Signal: Sell
For a thorough assessment of THAR stock, go to TipRanks’ Stock Analysis page.